Markets
Bundle of dollars and a bag of SPAC on scales.
(Getty Images)

SPACs are back — maybe just with the same old playbook and players

Many assets from the last boom still aren’t looking great.

Hyunsoo Rim
6/27/25 5:43AM

After a pandemic-era surge that ended in a wave of flameouts, Special Purpose Acquisition Companies (SPACs) — “blank-check” firms that raise money via IPO, then look to merge with a private company — are making a comeback.

According to Bloomberg, US SPACs have raised $11 billion so far in 2025, more than 5x the total at this point last year, and now account for nearly two-thirds of all US IPO volume. 

Driving the revival are some familiar names. Goldman Sachs is reportedly returning to the SPAC business after a three-year pause, only with a more selective approach. Chamath Palihapitiya, once dubbed the “SPAC King,” said last week he’ll “probably” launch another, as he concedes his last run “wasn’t a success by any means.” Meanwhile, regulatory tailwinds may be helping, with new SEC Chair Paul Atkins signaling a potential rollback of the stricter rules imposed under his predecessor.

However, cautionary specters from the 2020-21 SPAC frenzy still loom large.

Many of the pandemic-era cycle’s high-profile SPACs have cratered since their IPOs, due to overhyped projections, rising interest rates, and tougher scrutiny. Palihapitiya’s own deals — including Virgin Galactic, Clover Health, Opendoor, and Lucid — have mostly plunged 70% to 90% from their IPO prices (perhaps an explanation for why 71% of respondents in his recent X poll said he shouldn’t return). QuantumScape, despite jumping 35% yesterday, remains far from its peak, having never generated revenue, while several others have been delisted.

There are, of course, a few exceptions. Trump Media surged on political momentum despite its weak fundamentals; DraftKings has ridden the sports betting boom; SoFi Technologies remains a rare win from Palihapitiya with strong consumer traction; and Hims & Hers has built buzz in telehealth — though it certainly looks a little under the weather this week.

Yet many of the old problems persist. SPACs are once again chasing hyped sectors du jour, like crypto, quantum, and autonomous vehicles, and over 90% of completed SPAC deals now trade below their IPO price, per Reuters.

More Markets

See all Markets
markets

Broadcom’s post-earnings romp continues on heavy volumes

As Broadcom enjoys a rush of new orders from a major new customer (reported to be OpenAI), it’s also reveling in a flood of traffic into the stock.

Volumes are running at 2.5 times their daily average through 1:20 p.m. ET as traders continue to bid up shares in response to the brighter outlook for 2026 revenues, which sent the stock up 9.4% on Friday.

The chip designer is basking in a flood of price target hikes from Wall Street, with Bank of America, JPMorgan, Argus Research, Citigroup, Bernstein, Deutsche Bank, Morgan Stanley, Barclays, Piper Sandler, Rosenblatt Securities, Wells Fargo, and Susquehanna upping their view on how high shares can go since the company reported earnings last week.

Separately, Taiwanese industry outlet DigiTimes is reporting that orders from several other leading tech companies for custom-made Broadcom chips (or ASICs) are “already in the pipeline.” This report has not been corroborated by our own or any other publication’s reporting to date.

markets

SpaceX spectrum deal sends would-be rivals lower

Shares of struggling satellite services company EchoStar soared Monday, after the company — which had recently tottered close to bankruptcy — announced the sale of some of its wireless spectrum licenses to Tesla CEO Elon Musk’s SpaceX for $17 million.

The sale provides a competitive advantage to Musk’s growing Starlink satellite services business, as the licenses it is acquiring from Echostar allows Starlink to operate ground based broadband and cellphone services, the Wall Street Journal reported.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

markets

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.